Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Circulation. 2006;114:700-752
Published online before print August 2, 2006, doi: 10.1161/CIRCULATIONAHA.106.177031
Free Article
This Article
Free upon publication Free Article
Right arrow Full Text (PDF)
Right arrow Correction (v116,pe137)
Right arrow Correction (v116,pe137)
Right arrow All Versions of this Article:
114/7/700    most recent
CIRCULATIONAHA.106.177031v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fuster, V.
Right arrow Articles by Zamorano, J. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fuster, V.
Right arrow Articles by Zamorano, J. L.
Related Collections
Right arrow Anticoagulants
Right arrow Arrhythmias, clinical electrophysiology, drugs
Right arrow Cardiovascular Pharmacology
Right arrow Ablation/ICD/surgery
Right arrow Pacemaker

(Circulation. 2006;114:700-752.)
© 2006 American Heart Association, Inc.

ACC/AHA/ESC Practice Guidelines

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary

A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society

WRITING COMMITTEE: Valentin Fuster, MD, PhD, FACC, FAHA, FESC, Co-Chair; Lars E. Rydén, MD, PhD, FACC, FESC, FAHA, Co-Chair; David S. Cannom, MD, FACC; Harry J. Crijns, MD, FACC, FESC*; Anne B. Curtis, MD, FACC, FAHA; Kenneth A. Ellenbogen, MD, FACC{dagger}; Jonathan L. Halperin, MD, FACC, FAHA; Jean-Yves Le Heuzey, MD, FESC; G. Neal Kay, MD, FACC; James E. Lowe, MD, FACC; S. Bertil Olsson, MD, PhD, FESC; Eric N. Prystowsky, MD, FACC; Juan Luis Tamargo, MD, FESC; Samuel Wann, MD, FACC, FESC; ACC/AHA TASK FORCE MEMBERS; Sidney C. Smith, Jr, MD, FACC, FAHA, FESC, Chair; Alice K. Jacobs, MD, FACC, FAHA, Vice-Chair; Cynthia D. Adams, MSN, APRN-BC, FAHA; Jeffery L. Anderson, MD, FACC, FAHA; Elliott M. Antman, MD, FACC, FAHA{ddagger}; Jonathan L. Halperin, MD, FACC, FAHA; Sharon Ann Hunt, MD, FACC, FAHA; Rick Nishimura, MD, FACC, FAHA; Joseph P. Ornato, MD, FACC, FAHA; Richard L. Page, MD, FACC, FAHA; Barbara Riegel, DNSc, RN, FAHA; ESC COMMITTEE FOR PRACTICE GUIDELINES; Silvia G. Priori, MD, PhD, FESC, Chair; Jean-Jacques Blanc, MD, FESC, France; Andrzej Budaj, MD, FESC, Poland; A. John Camm, MD, FESC, FACC, FAHA, United Kingdom; Veronica Dean, France; Jaap W. Deckers, MD, FESC, The Netherlands; Catherine Despres, France; Kenneth Dickstein, MD, PhD, FESC, Norway; John Lekakis, MD, FESC, Greece; Keith McGregor, PhD, France; Marco Metra, MD, Italy; Joao Morais, MD, FESC, Portugal; Ady Osterspey, MD, Germany; Juan Luis Tamargo, MD, FESC, Spain; José Luis Zamorano, MD, FESC, Spain


Key Words: ACC/AHA/ESC Guidelines • atrial fibrillation • arrhythmia • heart rate • anticoagulants • antiarrhythmia agents • electrophysiology • pharmacology


*    TABLE OF CONTENTS
up arrowTop
 *TABLE OF CONTENTS
down arrowPreamble
 down arrowI. Introduction
 down arrowII. Definition
 down arrowIII. Classification
 down arrowIV. Epidemiology and Prognosis
 down arrowV. Pathophysiological Mechanisms
 down arrowVI. Causes, Associated...
 down arrowVII. Clinical Evaluation
 down arrowVIII. Management
 down arrowIX. Proposed Management...
 down arrowReferences
 

Preamble...702
   I. Introduction...702
      A. Organization of Committee and Evidence Review...702
         Classification of Recommendations...704
         Level of Evidence...704
      B. Changes Since the Initial Publication of These Guidelines in 2001...704
      C. Recommendations for Management of Patients With Atrial Fibrillation...704


Recommendations...704
   
  1.       Pharmacological Rate Control During Atrial Fibrillation...704
  2.       Preventing Thromboembolism...705
  3.       Cardioversion of Atrial Fibrillation...706
             a. Pharmacological Cardioversion...706
             b. Direct-Current Cardioversion...707
             c. Pharmacological Enhancement of Direct-Current Cardioversion...707
             d. Prevention of Thromboembolism in Patients With Atrial Fibrillation Undergoing Cardioversion...707

  4.       Maintenance of Sinus Rhythm...708
  5.       Special Considerations...708
             a. Postoperative Atrial Fibrillation...708
             b. Acute Myocardial Infarction...709
             c. Management of Atrial Fibrillation Associated With the Wolff-Parkinson-White (WPW) Preexcitation Syndrome...709
             d. Hyperthyroidism...709
             e. Management of Atrial Fibrillation During Pregnancy...709
             f. Management of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy (HCM)...710
             g. Management of Atrial Fibrillation in Patients With Pulmonary Disease...710


   II. Definition...710
      A. Atrial Fibrillation...710
      B. Related Arrhythmias...710

   III. Classification...711
   IV. Epidemiology and Prognosis...711
      A. Prevalence...712
      B. Incidence...712
      C. Prognosis...712

   V. Pathophysiological Mechanisms...712
      A. Atrial Factors...712
  1.          Atrial Pathology as a Cause of Atrial Fibrillation...712
  2.          Mechanisms of Atrial Fibrillation...712
  3.          Atrial Electrical Remodeling...713
  4.          Other Factors Contributing to Atrial Fibrillation...713

      B. Atrioventricular Conduction...713
  1.          General Aspects...713
  2.          Atrioventricular Conduction in Preexcitation Syndromes...714

      C. Myocardial and Hemodynamic Consequences of Atrial Fibrillation...714
      D. Thromboembolism...714
  1.          Pathophysiology of Thrombus Formation...714
  2.          Clinical Implications...715


   VI. Causes, Associated Conditions, Clinical Manifestations, and Quality of Life...715
      A. Causes and Associated Conditions...715
  1.          Reversible Causes of Atrial Fibrillation...715
  2.          Atrial Fibrillation Without Associated Heart Disease...715
  3.          Medical Conditions Associated With Atrial Fibrillation...715
  4.          Atrial Fibrillation With Associated Heart Disease...715
  5.          Familial Atrial Fibrillation...716
  6.          Autonomic Influences in Atrial Fibrillation...716

      B. Clinical Manifestations...716
      C. Quality of Life...716

   VII. Clinical Evaluation...716
      A. Basic Evaluation of the Patient With Atrial Fibrillation...716
  1.          Clinical History and Physical Examination...716
  2.          Investigations...716


   VIII. Management...718
      A. Strategic Objectives...718
      B. Pharmacological and Nonpharmacological Treatment Options...718
  1.          Heart Rate Control Versus Rhythm Control...718
                a. Pharmacological Rate Control During Atrial Fibrillation...720
                b. Regulation of Atrioventricular Nodal Conduction by Pacing...720
                c. Atrioventricular Nodal Ablation...720

  2.          Preventing Thromboembolism...722
                a. Risk Stratification...722
                b. Antithrombotic Strategies for Prevention of Ischemic Stroke and Systemic Embolism...723
                c. Nonpharmacological Approaches to Prevention of Thromboembolism...725

  3.          Cardioversion of Atrial Fibrillation...726
                a. Pharmacological Cardioversion...727

  4.          Pharmacological Agents to Maintain Sinus Rhythm...727
                a. Agents With Proven Efficacy to Maintain Sinus Rhythm...727
                b. Out-of-Hospital Initiation of Antiarrhythmic Drugs in Patients With Atrial Fibrillation...728

  5.          Direct-Current Cardioversion of Atrial Fibrillation and Atrial Flutter...731
                a. Technical and Procedural Aspects...731
                b. Risks and Complications of Direct-Current Cardioversion of Atrial Fibrillation...732
                c. Pharmacological Enhancement of Direct-Current Cardioversion...732
                d. Prevention of Thromboembolism in Patients With Atrial Fibrillation Undergoing Conversion...732

  6.          Maintenance of Sinus Rhythm...734
                a. Pharmacological Therapy...734
                b. Predictors of Recurrent Atrial Fibrillation...734
                c. General Approach to Antiarrhythmic Drug Therapy...734
                d. Selection of Antiarrhythmic Agents in Patients With Cardiac Diseases...735

  7.          Nonpharmacological Therapy for Atrial Fibrillation...735
                a. Surgical Ablation...735
                b. Catheter Ablation...736
                c. Suppression of Atrial Fibrillation Through Pacing...737
                d. Internal Atrial Defibrillators...737


      C. Primary Prevention...737

   IX. Proposed Management Strategies...737
      A. Overview of Algorithms for Management of Patients With Atrial Fibrillation...738
  1.          Newly Discovered Atrial Fibrillation...738
  2.          Recurrent Paroxysmal Atrial Fibrillation...738
  3.          Recurrent Persistent Atrial Fibrillation...739
  4.          Permanent Atrial Fibrillation...739



Appendix I...740
Appendix II...741
Appendix III...743
References...745


*    Preamble
up arrowTop
 up arrowTABLE OF CONTENTS
 *Preamble
down arrowI. Introduction
 down arrowII. Definition
 down arrowIII. Classification
 down arrowIV. Epidemiology and Prognosis
 down arrowV. Pathophysiological Mechanisms
 down arrowVI. Causes, Associated...
 down arrowVII. Clinical Evaluation
 down arrowVIII. Management
 down arrowIX. Proposed Management...
 down arrowReferences
 
It is important that the medical profession play a significant role in critically evaluating the use of diagnostic procedures and therapies as they are introduced and tested in the detection, management, or prevention of disease states. Rigorous and expert analysis of the available data documenting absolute and relative benefits and risks of those procedures and therapies can produce helpful guidelines that improve the effectiveness of care, optimize patient outcomes, and favorably affect the overall cost of care by focusing resources on the most effective strategies.

The American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) have jointly engaged in the production of such guidelines in the area of cardiovascular disease since 1980. The ACC/AHA Task Force on Practice Guidelines, whose charge is to develop, update, or revise practice guidelines for important cardiovascular diseases and procedures, directs this effort. The Task Force is pleased to have this guideline developed in conjunction with the European Society of Cardiology (ESC). Writing committees are charged with the task of performing an assessment of the evidence and acting as an independent group of authors to develop or update written recommendations for clinical practice.

Experts in the subject under consideration have been selected from all 3 organizations to examine subject-specific data and to write guidelines. The process includes additional representatives from other medical practitioner and specialty groups when appropriate. Writing committees are specifically charged to perform a formal literature review, weigh the strength of evidence for or against a particular treatment or procedure, and include estimates of expected health outcomes where data exist. Patient-specific modifiers, comorbidities, and issues of patient preference that might influence the choice of particular tests or therapies are considered as well as frequency of follow-up and cost-effectiveness. When available, information from studies on cost will be considered; however, review of data on efficacy and clinical outcomes will constitute the primary basis for preparing recommendations in these guidelines.

The ACC/AHA Task Force on Practice Guidelines and the ESC Committee for Practice Guidelines make every effort to avoid any actual, potential, or perceived conflict of interest that might arise as a result of an outside relationship or personal interest of the Writing Committee. Specifically, all members of the Writing Committee and peer reviewers of the document are asked to provide disclosure statements of all such relationships that might be perceived as real or potential conflicts of interest. Writing Committee members are also strongly encouraged to declare a previous relationship with industry that might be perceived as relevant to guideline development. If a Writing Committee member develops a new relationship with industry during his or her tenure, he or she is required to notify guideline staff in writing. The continued participation of the Writing Committee member will be reviewed. These statements are reviewed by the parent Task Force, reported orally to all members of the Writing Committee at each meeting, and updated and reviewed by the Writing Committee as changes occur. Please refer to the methodology manuals for further description of the policies used in guideline development, including relationships with industry, available on the ACC, AHA, and ESC World Wide Web sites (http://www.acc.org/clinical/manual/manual_introltr.htm, http://circ.ahajournals.org/manual/ and http://www.escardio.org/knowledge/guidelines/Rules/). Please see Appendix I for author relationships with industry and Appendix II for peer reviewer relationships with industry that are pertinent to these guidelines.

These practice guidelines are intended to assist healthcare providers in clinical decision making by describing a range of generally acceptable approaches for the diagnosis, management, and prevention of specific diseases and conditions. These guidelines attempt to define practices that meet the needs of most patients in most circumstances. These guideline recommendations reflect a consensus of expert opinion after a thorough review of the available, current scientific evidence and are intended to improve patient care. If these guidelines are used as the basis for regulatory/payer decisions, the ultimate goal is quality of care and serving the patient’s best interests. The ultimate judgment regarding care of a particular patient must be made by the healthcare provider and the patient in light of all of the circumstances presented by that patient. There are circumstances in which deviations from these guidelines are appropriate.

The guidelines will be reviewed annually by the ACC/AHA Task Force on Practice Guidelines and the ESC Committee for Practice Guidelines and will be considered current unless they are updated, revised, or sunsetted and withdrawn from distribution. The executive summary and recommendations are published in the August 15, 2006, issue of the Journal of the American College of Cardiology, August 15, 2006, issue of Circulation, and August 16, 2006, issue of the European Heart Journal. The full-text guidelines are e-published in the same issues of the Journal of the American College of Cardiology and Circulation and published in September 9, 2006, issue of Europace, as well as posted on the ACC (www.acc.org), AHA (www.americanheart.org), and ESC (www.escardio.org) World Wide Web sites. Copies of the full text and the executive summary are available from all 3 organizations.

Sidney C. Smith, Jr, MD, FACC, FAHA, FESC, Chair, ACC/AHA Task Force on Practice Guidelines

Silvia G. Priori, MD, PhD, FESC, Chair, ESC Committee for Practice Guidelines


*    I. Introduction
up arrowTop
 up arrowTABLE OF CONTENTS
 up arrowPreamble
 *I. Introduction
down arrowII. Definition
 down arrowIII. Classification
 down arrowIV. Epidemiology and Prognosis
 down arrowV. Pathophysiological Mechanisms
 down arrowVI. Causes, Associated...
 down arrowVII. Clinical Evaluation
 down arrowVIII. Management
 down arrowIX. Proposed Management...
 down arrowReferences
 
A. Organization of Committee and Evidence Review
Atrial fibrillation (AF) is the most common sustained cardiac rhythm disturbance, increasing in prevalence with age. AF is often associated with structural heart disease, although a substantial proportion of patients with AF have no detectable heart disease. Hemodynamic impairment and thromboembolic events related to AF result in significant morbidity, mortality, and cost. Accordingly, the American College of Cardiology (ACC), the American Heart Association (AHA), and the European Society of Cardiology (ESC) created a committee to establish guidelines for optimum management of this frequent and complex arrhythmia.

The committee was composed of representatives of the ACC, AHA, ESC, the European Heart Rhythm Association (EHRA), and the Heart Rhythm Society (HRS). The document was reviewed by reviewers nominated by these organizations and will be reviewed annually by the Task Force and considered current unless the Task Force revises or withdraws it from distribution.

The ACC/AHA/ESC Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation conducted a comprehensive review of the relevant literature from 2001 to 2006 using the PubMed/MEDLINE and Cochrane Library databases. Searches focused on English-language sources and studies in human subjects. Articles related to animal experimentation were cited when important to understanding concepts pertinent to patient management.

Classification of Recommendations

Level of Evidence
The weight of evidence was ranked from highest (A) to lowest (C), as follows:

B. Changes Since the Initial Publication of These Guidelines in 2001
The Writing Committee considered evidence published since 2001 and drafted revised recommendations to incorporate results from major clinical trials such as those that compared rhythm control and rate control approaches to long-term management. The text has been reorganized to reflect the implications for patient care, beginning with recognition of AF and its pathogenesis and the general priorities of rate control, prevention of thromboembolism, and methods available for use in selected patients to correct the arrhythmia and maintain normal sinus rhythm. Advances in catheter-based ablation technologies are incorporated in expanded sections and recommendations, with the recognition that such vital details as patient selection, optimum catheter positioning, absolute rates of treatment success, and the frequency of complications remain incompletely defined. Sections on drug therapy have been confined to human studies with compounds approved for clinical use in North America and/or Europe. As data on the management of patients prone to AF in special circumstances are more robust, recommendations are based on a higher level of evidence than in the first edition of these guidelines. Every effort was made to maintain consistency with other ACC/AHA and ESC practice guidelines.

C. Recommendations for Management of Patients With Atrial Fibrillation
Classification of Recommendations and Level of Evidence are expressed in the ACC/AHA/ESC format as follows and described in Table 1. Recommendations are evidence based and derived primarily from published data. The reader is referred to the full-text guidelines for a complete description of the rationale and evidence supporting these recommendations.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Applying Classification of Recommendations and Level of Evidence{dagger}

Recommendations

  1. Pharmacological Rate Control During Atrial Fibrillation
       Class I
    1.       Measurement of the heart rate at rest and control of the rate using pharmacological agents (either a beta blocker or nondihydropyridine calcium channel antagonist, in most cases) are recommended for patients with persistent or permanent AF. (Level of Evidence: B)
    2.       In the absence of preexcitation, intravenous administration of beta blockers (esmolol, metoprolol, or propranolol) or nondihydropyridine calcium channel antagonists (verapamil, diltiazem) is recommended to slow the ventricular response to AF in the acute setting, exercising caution in patients with hypotension or heart failure (HF). (Level of Evidence: B)
    3.       Intravenous administration of digoxin or amiodarone is recommended to control the heart rate in patients with AF and HF who do not have an accessory pathway. (Level of Evidence: B)
    4.       In patients who experience symptoms related to AF during activity, the adequacy of heart rate control should be assessed during exercise, adjusting pharmacological treatment as necessary to keep the rate in the physiological range. (Level of Evidence: C)
    5.       Digoxin is effective following oral administration to control the heart rate at rest in patients with AF and is indicated for patients with HF, left ventricular (LV) dysfunction, or for sedentary individuals. (Level of Evidence: C)

       Class IIa
    1.       A combination of digoxin and either a beta blocker or nondihydropyridine calcium channel antagonist is reasonable to control the heart rate both at rest and during exercise in patients with AF. The choice of medication should be individualized and the dose modulated to avoid bradycardia. (Level of Evidence: B)
    2.       It is reasonable to use ablation of the AV node or accessory pathway to control heart rate when pharmacological therapy is insufficient or associated with side effects. (Level of Evidence: B)
    3.       Intravenous amiodarone can be useful to control the heart rate in patients with AF when other measures are unsuccessful or contraindicated. (Level of Evidence: C)
    4.       When electrical cardioversion is not necessary in patients with AF and an accessory pathway, intravenous procainamide or ibutilide is a reasonable alternative. (Level of Evidence: C)

       Class IIb
    1.       When the ventricular rate cannot be adequately controlled both at rest and during exercise in patients with AF using a beta blocker, nondihydropyridine calcium channel antagonist, or digoxin, alone or in combination, oral amiodarone may be administered to control the heart rate. (Level of Evidence: C)
    2.       Intravenous procainamide, disopyramide, ibutilide, or amiodarone may be considered for hemodynamically stable patients with AF involving conduction over an accessory pathway. (Level of Evidence: B)
    3.       When the rate cannot be controlled with pharmacological agents or tachycardia-mediated cardiomyopathy is suspected, catheter-directed ablation of the AV node may be considered in patients with AF to control the heart rate. (Level of Evidence: C)

       Class III
    1.       Digitalis should not be used as the sole agent to control the rate of ventricular response in patients with paroxysmal AF. (Level of Evidence: B)
    2.       Catheter ablation of the AV node should not be attempted without a prior trial of medication to control the ventricular rate in patients with AF. (Level of Evidence: C)
    3.       In patients with decompensated HF and AF, intravenous administration of a nondihydropyridine calcium channel antagonist may exacerbate hemodynamic compromise and is not recommended. (Level of Evidence: C)
    4.       Intravenous administration of digitalis glycosides or nondihydropyridine calcium channel antagonists to patients with AF and a preexcitation syndrome may paradoxically accelerate the ventricular response and is not recommended. (Level of Evidence: C)


  2. Preventing Thromboembolism (For recommendations regarding antithrombotic therapy in patients with AF undergoing cardioversion, see Section I.C.3.d.)
       Class I
    1.       Antithrombotic therapy to prevent thromboembolism is recommended for all patients with AF, except those with lone AF or contraindications. (Level of Evidence: A)
    2.       The selection of the antithrombotic agent should be based upon the absolute risks of stroke and bleeding and the relative risk and benefit for a given patient. (Level of Evidence: A)
    3.       For patients without mechanical heart valves at high risk of stroke, chronic oral anticoagulant therapy with a vitamin K antagonist is recommended in a dose adjusted to achieve the target intensity international normalized ratio (INR) of 2.0 to 3.0, unless contraindicated. Factors associated with highest risk for stroke in patients with AF are prior thromboembolism (stroke, transient ischemic attack [TIA], or systemic embolism) and rheumatic mitral stenosis. (Level of Evidence: A)
    4.       Anticoagulation with a vitamin K antagonist is recommended for patients with more than 1 moderate risk factor. Such factors include age 75 y or greater, hypertension, HF, impaired LV systolic function (ejection fraction 35% or less or fractional shortening less than 25%), and diabetes mellitus. (Level of Evidence: A)
    5.       INR should be determined at least weekly during initiation of therapy and monthly when anticoagulation is stable. (Level of Evidence: A)
    6.       Aspirin, 81–325 mg daily, is recommended as an alternative to vitamin K antagonists in low-risk patients or in those with contraindications to oral anticoagulation. (Level of Evidence: A)
    7.       For patients with AF who have mechanical heart valves, the target intensity of anticoagulation should be based on the type of prosthesis, maintaining an INR of at least 2.5. (Level of Evidence: B)
    8.       Antithrombotic therapy is recommended for patients with atrial flutter as for those with AF. (Level of Evidence: C)

       Class IIa
    1.       For primary prevention of thromboembolism in patients with nonvalvular AF who have just 1 of the following validated risk factors, antithrombotic therapy with either aspirin or a vitamin K antagonist is reasonable, based upon an assessment of the risk of bleeding complications, ability to safely sustain adjusted chronic anticoagulation, and patient preferences: age greater than or equal to 75 y (especially in female patients), hypertension, HF, impaired LV function, or diabetes mellitus. (Level of Evidence: A)
    2.       For patients with nonvalvular AF who have 1 or more of the following less well-validated risk factors, antithrombotic therapy with either aspirin or a vitamin K antagonist is reasonable for prevention of thromboembolism: age 65 to 74 y, female gender, or CAD. The choice of agent should be based upon the risk of bleeding complications, ability to safely sustain adjusted chronic anticoagulation, and patient preferences. (Level of Evidence: B)
    3.       It is reasonable to select antithrombotic therapy using the same criteria irrespective of the pattern (i.e., paroxysmal, persistent, or permanent) of AF. (Level of Evidence: B)
    4.       In patients with AF who do not have mechanical prosthetic heart valves, it is reasonable to interrupt anticoagulation for up to 1 wk without substituting heparin for surgical or diagnostic procedures that carry a risk of bleeding. (Level of Evidence: C)
    5.       It is reasonable to reevaluate the need for anticoagulation at regular intervals. (Level of Evidence: C)

       Class IIb
    1.       In patients 75 y of age and older at increased risk of bleeding but without frank contraindications to oral anticoagulant therapy, and in other patients with moderate risk factors for thromboembolism who are unable to safely tolerate anticoagulation at the standard intensity of INR 2.0 to 3.0, a lower INR target of 2.0 (range 1.6 to 2.5) may be considered for primary prevention of ischemic stroke and systemic embolism. (Level of Evidence: C)
    2.       When surgical procedures require interruption of oral anticoagulant therapy for longer than 1 wk in high-risk patients, unfractionated heparin may be administered or low-molecular-weight heparin given by subcutaneous injection, although the efficacy of these alternatives in this situation is uncertain. (Level of Evidence: C)
    3.       Following percutaneous coronary intervention or revascularization surgery in patients with AF, low-dose aspirin (less than 100 mg per d) and/or clopidogrel (75 mg per d) may be given concurrently with anticoagulation to prevent myocardial ischemic events, but these strategies have not been thoroughly evaluated and are associated with an increased risk of bleeding. (Level of Evidence: C)
    4.       In patients undergoing percutaneous coronary intervention, anticoagulation may be interrupted to prevent bleeding at the site of peripheral arterial puncture, but the vitamin K antagonist should be resumed as soon as possible after the procedure and the dose adjusted to achieve an INR in the therapeutic range. Aspirin may be given temporarily during the hiatus, but the maintenance regimen should then consist of the combination of clopidogrel, 75 mg daily, plus warfarin (INR 2.0 to 3.0). Clopidogrel should be given for a minimum of 1 mo after implantation of a bare metal stent, at least 3 mo for a sirolimus-eluting stent, at least 6 mo for a paclitaxel-eluting stent, and 12 mo or longer in selected patients, following which warfarin may be continued as monotherapy in the absence of a subsequent coronary event. When warfarin is given in combination with clopidogrel or low-dose aspirin, the dose intensity must be carefully regulated. (Level of Evidence: C)
    5.       In patients with AF younger than 60 y without heart disease or risk factors for thromboembolism (lone AF), the risk of thromboembolism is low without treatment and the effectiveness of aspirin for primary prevention of stroke relative to the risk of bleeding has not been established. (Level of Evidence: C)
    6.       In patients with AF who sustain ischemic stroke or systemic embolism during treatment with low-intensity anticoagulation (INR 2.0 to 3.0), rather than add an antiplatelet agent, it may be reasonable to raise the intensity of the anticoagulation to a maximum target INR of 3.0 to 3.5. (Level of Evidence: C)

       Class III
          Long-term anticoagulation with a vitamin K antagonist is not recommended for primary prevention of stroke in patients below the age of 60 y without heart disease (lone AF) or any risk factors for thromboembolism. (Level of Evidence: C)


  3. Cardioversion of Atrial Fibrillation
       a. Pharmacological Cardioversion
          Class I
    1.          Administration of flecainide, dofetilide, propafenone, or ibutilide is recommended for pharmacological cardioversion of AF. (Level of Evidence: A)

          Class IIa
    1.          Administration of amiodarone is a reasonable option for pharmacological cardioversion of AF. (Level of Evidence: A)
    2.          A single oral bolus dose of propafenone or flecainide ("pill-in-the-pocket") can be administered to terminate persistent AF outside the hospital once treatment has proved safe in hospital for selected patients without sinus or AV node dysfunction, bundle-branch block, QT-interval prolongation, the Brugada syndrome, or structural heart disease. Before antiarrhythmic medication is initiated, a beta blocker or nondihydropyridine calcium channel antagonist should be given to prevent rapid AV conduction in the event atrial flutter occurs. (Level of Evidence: C)
    3.          Administration of amiodarone can be beneficial on an outpatient basis in patients with paroxysmal or persistent AF when rapid restoration of sinus rhythm is not deemed necessary. (Level of Evidence: C)

          Class IIb
             Administration of quinidine or procainamide might be considered for pharmacological cardioversion of AF, but the usefulness of these agents is not well established. (Level of Evidence: C)

          Class III
    1.          Digoxin and sotalol may be harmful when used for pharmacological cardioversion of AF and are not recommended. (Level of Evidence: A)
    2.          Quinidine, procainamide, disopyramide, and dofetilide should not be started out of hospital for conversion of AF to sinus rhythm. (Level of Evidence: B)


       b. Direct-Current Cardioversion
          Class I
    1.          When a rapid ventricular response does not respond promptly to pharmacological measures for patients with AF with ongoing myocardial ischemia, symptomatic hypotension, angina, or HF, immediate R-wave synchronized direct-current cardioversion is recommended. (Level of Evidence: C)
    2.          Immediate direct-current cardioversion is recommended for patients with AF involving preexcitation when very rapid tachycardia or hemodynamic instability occurs. (Level of Evidence: B)
    3.          Cardioversion is recommended in patients without hemodynamic instability when symptoms of AF are unacceptable to the patient. In case of early relapse of AF after cardioversion, repeated direct-current cardioversion attempts may be made following administration of antiarrhythmic medication. (Level of Evidence: C)

          Class IIa
    1.          Direct-current cardioversion can be useful to restore sinus rhythm as part of a long-term management strategy for patients with AF. (Level of Evidence: B)
    2.          Patient preference is a reasonable consideration in the selection of infrequently repeated cardioversions for the management of symptomatic or recurrent AF. (Level of Evidence: C)

          Class III
    1.          Frequent repetition of direct-current cardioversion is not recommended for patients who have relatively short periods of sinus rhythm between relapses of AF after multiple cardioversion procedures despite prophylactic antiarrhythmic drug therapy. (Level of Evidence: C)
    2.          Electrical cardioversion is contraindicated in patients with digitalis toxicity or hypokalemia. (Level of Evidence: C)


       c. Pharmacological Enhancement of Direct-Current Cardioversion
          Class IIa
    1.          Pretreatment with amiodarone, flecainide, ibutilide, propafenone, or sotalol can be useful to enhance the success of direct-current cardioversion and prevent recurrent AF. (Level of Evidence: B)
    2.          In patients who relapse to AF after successful cardioversion, it can be useful to repeat the procedure following prophylactic administration of antiarrhythmic medication. (Level of Evidence: C)

          Class IIb
    1.          For patients with persistent AF, administration of beta blockers, disopyramide, diltiazem, dofetilide, procainamide, or verapamil may be considered, although the efficacy of these agents to enhance the success of direct-current cardioversion or to prevent early recurrence of AF is uncertain. (Level of Evidence: C)
    2.          Out-of-hospital initiation of antiarrhythmic medications may be considered in patients without heart disease to enhance the success of cardioversion of AF. (Level of Evidence: C)
    3.          Out-of-hospital administration of antiarrhythmic medications may be considered to enhance the success of cardioversion of AF in patients with certain forms of heart disease once the safety of the drug has been verified for the patient. (Level of Evidence: C)


       d. Prevention of Thromboembolism in Patients With Atrial Fibrillation Undergoing Cardioversion
          Class I
    1.          For patients with AF of 48-h duration or longer, or when the duration of AF is unknown, anticoagulation (INR 2.0 to 3.0) is recommended for at least 3 wk prior to and 4 wk after cardioversion, regardless of the method (electrical or pharmacological) used to restore sinus rhythm. (Level of Evidence: B)
    2.          For patients with AF of more than 48-h duration requiring immediate cardioversion because of hemodynamic instability, heparin should be administered concurrently (unless contraindicated) by an initial intravenous bolus injection followed by a continuous infusion in a dose adjusted to prolong the activated partial thromboplastin time to 1.5 to 2 times the reference control value. Thereafter, oral anticoagulation (INR 2.0 to 3.0) should be provided for at least 4 wk, as for patients undergoing elective cardioversion. Limited data support subcutaneous administration of low-molecular-weight heparin in this indication. (Level of Evidence: C)
    3.          For patients with AF of less than 48-h duration associated with hemodynamic instability (angina pectoris, myocardial infarction [MI], shock, or pulmonary edema), cardioversion should be performed immediately without delay for prior initiation of anticoagulation. (Level of Evidence: C)

          Class IIa
    1.          During the 48 h after onset of AF, the need for anticoagulation before and after cardioversion may be based on the patient’s risk of thromboembolism. (Level of Evidence: C)
    2.          As an alternative to anticoagulation prior to cardioversion of AF, it is reasonable to perform transesophageal echocardiography (TEE) in search of thrombus in the left atrium (LA) or left atrial appendage (LAA). (Level of Evidence: B)
                  2a. For patients with no identifiable thrombus, cardioversion is reasonable immediately after anticoagulation with unfractionated heparin (e.g., initiated by intravenous bolus injection and an infusion continued at a dose adjusted to prolong the activated partial thromboplastin time to 1.5 to 2 times the control value until oral anticoagulation has been established with an oral vitamin K antagonist (e.g., warfarin) as evidenced by an INR equal to or greater than2.0). (Level of Evidence: B)Thereafter, continuation of oral anticoagulation (INR 2.0 to 3.0) is reasonable for a total anticoagulation period of at least 4 wk, as for patients undergoing elective cardioversion. (Level of Evidence: B)Limited data are available to support the subcutaneous administration of a low-molecular-weight heparin in this indication. (Level of Evidence: C)
                  2b. For patients in whom thrombus is identified by TEE, oral anticoagulation (INR 2.0 to 3.0) is reasonable for at least 3 wk prior to and 4 wk after restoration of sinus rhythm, and a longer period of anticoagulation may be appropriate even after apparently successful cardioversion, because the risk of thromboembolism often remains elevated in such cases. (Level of Evidence: C)

    3.          For patients with atrial flutter undergoing cardioversion, anticoagulation can be beneficial according to the recommendations as for patients with AF. (Level of Evidence: C)



  4. Maintenance of Sinus Rhythm
       Class I
          Before initiating antiarrhythmic drug therapy, treatment of precipitating or reversible causes of AF is recommended. (Level of Evidence: C)

       Class IIa
    1.       Pharmacological therapy can be useful in patients with AF to maintain sinus rhythm and prevent tachycardia-induced cardiomyopathy. (Level of Evidence: C)
    2.       Infrequent, well-tolerated recurrence of AF is reasonable as a successful outcome of antiarrhythmic drug therapy. (Level of Evidence: C)
    3.       Outpatient initiation of antiarrhythmic drug therapy is reasonable in patients with AF who have no associated heart disease when the agent is well tolerated. (Level of Evidence: C)
    4.       In patients with lone AF without structural heart disease, initiation of propafenone or flecainide can be beneficial on an outpatient basis in patients with paroxysmal AF who are in sinus rhythm at the time of drug initiation. (Level of Evidence: B)
    5.       Sotalol can be beneficial in outpatients in sinus rhythm with little or no heart disease, prone to paroxysmal AF, if the baseline uncorrected QT interval is less than 460 ms, serum electrolytes are normal, and risk factors associated with class III drug–related proarrhythmia are not present. (Level of Evidence: C)
    6.       Catheter ablation is a reasonable alternative to pharmacological therapy to prevent recurrent AF in symptomatic patients with little or no LA enlargement. (Level of Evidence: C)

       Class III
    1.       Antiarrhythmic therapy with a particular drug is not recommended for maintenance of sinus rhythm in patients with AF who have well-defined risk factors for proarrhythmia with that agent. (Level of Evidence: A)
    2.       Pharmacological therapy is not recommended for maintenance of sinus rhythm in patients with advanced sinus node disease or atrioventricular (AV) node dysfunction unless they have a functioning electronic cardiac pacemaker. (Level of Evidence: C)


  5. Special Considerations
       a. Postoperative Atrial Fibrillation
          Class I
    1.          Unless contraindicated, treatment with an oral beta blocker to prevent postoperative AF is recommended for patients undergoing cardiac surgery. (Level of Evidence: A)
    2.          Administration of AV nodal blocking agents is recommended to achieve rate control in patients who develop postoperative AF. (Level of Evidence: B)

          Class IIa
    1.          Preoperative administration of amiodarone reduces the incidence of AF in patients undergoing cardiac surgery and represents appropriate prophylactic therapy for patients at high risk for postoperative AF. (Level of Evidence: A)
    2.          It is reasonable to restore sinus rhythm by pharmacological cardioversion with ibutilide or direct-current cardioversion in patients who develop postoperative AF as advised for nonsurgical patients. (Level of Evidence: B)
    3.          It is reasonable to administer antiarrhythmic medications in an attempt to maintain sinus rhythm in patients with recurrent or refractory postoperative AF, as recommended for other patients who develop AF. (Level of Evidence: B)
    4.          It is reasonable to administer antithrombotic medication in patients who develop postoperative AF, as recommended for nonsurgical patients. (Level of Evidence: B)

          Class IIb
             Prophylactic administration of sotalol may be considered for patients at risk of developing AF following cardiac surgery. (Level of Evidence: B)


       b. Acute Myocardial Infarction
          Class I
    1.          Direct-current cardioversion is recommended for patients with severe hemodynamic compromise or intractable ischemia, or when adequate rate control cannot be achieved with pharmacological agents in patients with acute MI and AF. (Level of Evidence: C)
    2.          Intravenous administration of amiodarone is recommended to slow a rapid ventricular response to AF and improve LV function in patients with acute MI. (Level of Evidence: C)
    3.          Intravenous beta blockers and nondihydropyridine calcium antagonists are recommended to slow a rapid ventricular response to AF in patients with acute MI who do not display clinical LV dysfunction, bronchospasm, or AV block. (Level of Evidence: C)
    4.          For patients with AF and acute MI, administration of unfractionated heparin by either continuous intravenous infusion or intermittent subcutaneous injection is recommended in a dose sufficient to prolong the activated partial thromboplastin time to 1.5 to 2 times the control value, unless contraindications to anticoagulation exist. (Level of Evidence: C)

          Class IIa
             Intravenous administration of digitalis is reasonable to slow a rapid ventricular response and improve LV function in patients with acute MI and AF associated with severe LV dysfunction and HF. (Level of Evidence: C)

          Class III
             The administration of class IC antiarrhythmic drugs is not recommended in patients with AF in the setting of acute MI. (Level of Evidence: C)


       c. Management of Atrial Fibrillation Associated With the Wolff-Parkinson-White (WPW) Preexcitation Syndrome
          Class I
    1.          Catheter ablation of the accessory pathway is recommended in symptomatic patients with AF who have WPW syndrome, particularly those with syncope due to rapid heart rate or those with a short bypass tract refractory period. (Level of Evidence: B)
    2.          Immediate direct-current cardioversion is recommended to prevent ventricular fibrillation in patients with a short anterograde bypass tract refractory period in whom AF occurs with a rapid ventricular response associated with hemodynamic instability. (Level of Evidence: B)
    3.          Intravenous procainamide or ibutilide is recommended to restore sinus rhythm in patients with WPW in whom AF occurs without hemodynamic instability in association with a wide QRS complex on the electrocardiogram (ECG) (greater than or equal to 120-ms duration) or with a rapid preexcited ventricular response. (Level of Evidence: C)

          Class IIa
             Intravenous flecainide or direct-current cardioversion is reasonablewhen very rapid ventricular rates occur in patients with AF involving conduction over an accessory pathway. (Level of Evidence: B)

          Class IIb
             It may be reasonable to administer intravenous quinidine, procainamide, disopyramide, ibutilide, or amiodarone to hemodynamically stable patients with AF involving conduction over an accessory pathway. (Level of Evidence: B)

          Class III
             Intravenous administration of digitalis glycosides or nondihydropyridine calcium channel antagonists is not recommended in patients with WPW syndrome who have preexcited ventricular activation during AF. (Level of Evidence: B)


       d. Hyperthyroidism
          Class I
    1.          Administration of a beta blocker is recommended to control the rate of ventricular response in patients with AF complicating thyrotoxicosis, unless contraindicated. (Level of Evidence: B)
    2.          In circumstances when a beta blocker cannot be used, administration of a nondihydropyridine calcium channel antagonist (diltiazem or verapamil) is recommended to control the ventricular rate in patients with AF and thyrotoxicosis. (Level of Evidence: B)
    3.          In patients with AF associated with thyrotoxicosis, oral anticoagulation (INR 2.0 to 3.0) is recommended to prevent thromboembolism, as recommended for AF patients with other risk factors for stroke. (Level of Evidence: C)
    4.          Once a euthyroid state is restored, recommendations for antithrombotic prophylaxis are the same as for patients without hyperthyroidism. (Level of Evidence: C)


       e. Management of Atrial Fibrillation During Pregnancy
          Class I
    1.          Digoxin, a beta blocker, or a nondihydropyridine calcium channel antagonist is recommended to control the rate of ventricular response in pregnant patients with AF. (Level of Evidence: C)
    2.          Direct-current cardioversion is recommended in pregnant patients who become hemodynamically unstable due to AF. (Level of Evidence: C)
    3.          Protection against thromboembolism is recommended throughout pregnancy for all patients with AF (except those with lone AF and/or low thromboembolic risk). Therapy (anticoagulant or aspirin) should be chosen according to the stage of pregnancy. (Level of Evidence: C)

          Class IIb
    1.          Administration of heparin may be considered during the first trimester and last month of pregnancy for patients with AF and risk factors for thromboembolism. Unfractionated heparin may be administered either by continuous intravenous infusion in a dose sufficient to prolong the activated partial thromboplastin time to 1.5 to 2 times the control value or by intermittent subcutaneous injection in a dose of 10 000 to 20 000 units every 12 h, adjusted to prolong the mid-interval (6 h after injection) activated partial thromboplastin time to 1.5 times control. (Level of Evidence: B)
    2.          Despite the limited data available, subcutaneous administration of low-molecular-weight heparin may be considered during the first trimester and last month of pregnancy for patients with AF and risk factors for thromboembolism. (Level of Evidence: C)
    3.          Administration of an oral anticoagulant may be considered during the second trimester for pregnant patients with AF at high thromboembolic risk. (Level of Evidence: C)
    4.          Administration of quinidine or procainamide may be considered to achieve pharmacological cardioversion in hemodynamically stable patients who develop AF during pregnancy. (Level of Evidence: C)


       f. Management of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy (HCM)
          Class I
             Oral anticoagulation (INR 2.0 to 3.0) is recommended in patients with HCM who develop AF, as for other patients at high risk of thromboembolism. (Level of Evidence: B)

          Class IIa
             Antiarrhythmic medications can be useful to prevent recurrent AF in patients with HCM. Available data are insufficient to recommend one agent over another in this situation, but (a) disopyramide combined with a beta blocker or nondihydropyridine calcium channel antagonist or (b) amiodarone alone is generally preferred. (Level of Evidence: C)


       g. Management of Atrial Fibrillation in Patients With Pulmonary Disease
          Class I
    1.          Correction of hypoxemia and acidosis is the recommended primary therapeutic measurefor patients who develop AF during an acute pulmonary illness or exacerbation of chronic pulmonary disease. (Level of Evidence: C)
    2.          A nondihydropyridine calcium channel antagonist (diltiazem or verapamil) is recommended to control the ventricular rate in patients with obstructive pulmonary disease who develop AF. (Level of Evidence: C)
    3.          Direct-current cardioversion should be attempted in patients with pulmonary disease who become hemodynamically unstable as a consequence of AF. (Level of Evidence: C)

          Class III
    1.          Theophylline and beta-adrenergic agonist agents are not recommended in patients with bronchospastic lung disease who develop AF. (Level of Evidence: C)
    2.          Beta blockers, sotalol, propafenone, and adenosine are not recommended in patients with obstructive lung disease who develop AF. (Level of Evidence: C)




*    II. Definition
up arrowTop
 up arrowTABLE OF CONTENTS
 up arrowPreamble
 up arrowI. Introduction
 *II. Definition
down arrowIII. Classification
 down arrowIV. Epidemiology and Prognosis
 down arrowV. Pathophysiological Mechanisms
 down arrowVI. Causes, Associated...
 down arrowVII. Clinical Evaluation
 down arrowVIII. Management
 down arrowIX. Proposed Management...
 down arrowReferences
 
A. Atrial Fibrillation
AF is a supraventricular tachyarrhythmia characterized by uncoordinated atrial activation with consequent deterioration of mechanical function. On the ECG, rapid oscillations, or fibrillatory waves that vary in amplitude, shape, and timing, replace consistent P waves, and there is an irregular ventricular response that is rapid when conduction is intact.1 The ventricular response depends on electrophysiological properties of the AV node and other conducting tissues, vagal and sympathetic tone, the presence or absence of accessory pathways, and the action of drugs.2 When AV block or ventricular or AV junctional tachycardia is present, the cardiac cycles (R-R intervals) may be regular. In patients with pacemakers, diagnosis of AF may require pacemaker inhibition to expose fibrillatory activity. An irregular, sustained, wide-QRS-complex tachycardia suggests AF with conduction over an accessory pathway or AF with bundle-branch block. Atrial flutter is usually readily distinguished from AF. Extremely rapid rates (greater than 200 beats per minute) suggest an accessory pathway or ventricular tachycardia.

B. Related Arrhythmias
AF may occur in association with atrial flutter or atrial tachycardia. The typical form of atrial flutter is characterized by a saw-tooth pattern of regular atrial activation called flutter (f) waves on the ECG, particularly visible in leads II, III, aVF, and V1. If untreated, the atrial rate typically ranges from 240 to 320 beats per minute, with f waves inverted in ECG leads II, III, and aVF and upright in lead V1. The direction of activation in the right atrium (RA) may be reversed, resulting in upright f waves in leads II, III, and aVF and inversion in lead V1. Atrial flutter may degenerate into AF, and AF may convert to atrial flutter. Atrial flutter is usually readily distinguished from AF, but misdiagnosis may occur when fibrillatory atrial activity is prominent in more than 1 ECG lead.3

Focal atrial tachycardias, AV reentrant tachycardias, and AV nodal reentrant tachycardias may also trigger AF. In these tachycardias, distinct P waves are typically separated by an isoelectric baseline, and their morphology may localize the origin of the arrhythmia.


*    III. Classification
up arrowTop
 up arrowTABLE OF CONTENTS
 up arrowPreamble
 up arrowI. Introduction
 up arrowII. Definition
 *III. Classification
down arrowIV. Epidemiology and Prognosis
 down arrowV. Pathophysiological Mechanisms
 down arrowVI. Causes, Associated...
 down arrowVII. Clinical Evaluation
 down arrowVIII. Management
 down arrowIX. Proposed Management...
 down arrowReferences
 
Various classification systems have been proposed for AF based on the ECG pattern,1 epicardial4 or endocavitary recordings, mapping of atrial electrical activity, or clinical features. Although the pattern of AF can change over time, it may be helpful to characterize the arrhythmia at a given moment. The classification scheme recommended here represents a consensus driven by a desire for simplicity and clinical relevance.

The clinician should distinguish a first-detected episode of AF, whether or not symptomatic or self-limited, recognizing the uncertainty about the actual duration of the episode and about previous undetected episodes (Fig. 1). After 2 or more episodes, AF is considered recurrent. If the arrhythmia terminates spontaneously, recurrent AF is designated paroxysmal; when sustained beyond 7 d, it is termed persistent. Termination with pharmacological therapy or direct-current cardioversion does not alter the designation. First-detected AF may be either paroxysmal or persistent. The category of persistent AF also includes cases of long-standing AF (e.g., longer than 1 y), usually leading to permanent AF, in which cardioversion has failed or has been foregone.


Figure 1177031
View larger version (13K):
[in this window]
[in a new window]
  		Figure 1. Patterns of atrial fibrillation (AF). 1, Episodes that generally last 7 d or less (most less than 24 h); 2, episodes that usually last more than 7 d; 3, cardioversion failed or not attempted; and 4, both paroxysmal and persistent AF may be recurrent.

These categories are not mutually exclusive, and a particular patient may have several episodes of paroxysmal AF and occasional persistent AF, or the reverse, but it is practical to categorize a given patient by his or her most frequent presentation. The definition of permanent AF is often arbitrary, and the duration refers both to individual episodes and to how long the diagnosis has been present in a given patient. Thus, in a patient with paroxysmal AF, episodes lasting seconds to hours may occur repeatedly for years.

This terminology applies to episodes lasting longer than 30 s without a reversible cause. Secondary AF in the setting of acute MI, cardiac surgery, pericarditis, myocarditis, hyperthyroidism, or acute pulmonary disease is considered separately. In these situations, AF is not the primary problem, and concurrent treatment of the underlying disorder usually terminates the arrhythmia. Conversely, when AF occurs in the course of a concurrent disorder like well-controlled hypothyroidism, the general principles for management of the arrhythmia apply.

The term lone AF applies to individuals younger than 60 y without clinical or echocardiographic evidence of cardiopulmonary disease, including hypertension.5 These patients have a favorable prognosis with respect to thromboembolism and mortality. Over time, patients move out of the lone AF category due to aging or development of cardiac abnormalities such as enlargement of the LA, and the risks of thromboembolism and mortality rise. The term nonvalvular AF refers to cases without rheumatic mitral